000777914 000__ 03432cam\a2200481Ii\4500
000777914 001__ 777914
000777914 005__ 20230306142741.0
000777914 006__ m\\\\\o\\d\\\\\\\\
000777914 007__ cr\nn\nnnunnun
000777914 008__ 161116s2017\\\\sz\\\\\\ob\\\\000\0\eng\d
000777914 019__ $$a962795411$$a965707391$$a966567309$$a974651499$$a981101617
000777914 020__ $$a9783319460079$$q(electronic book)
000777914 020__ $$a3319460072$$q(electronic book)
000777914 020__ $$z9783319460055
000777914 020__ $$z3319460056
000777914 0247_ $$a10.1007/978-3-319-46007-9$$2doi
000777914 035__ $$aSP(OCoLC)ocn962750908
000777914 035__ $$aSP(OCoLC)962750908$$z(OCoLC)962795411$$z(OCoLC)965707391$$z(OCoLC)966567309$$z(OCoLC)974651499$$z(OCoLC)981101617
000777914 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dIDEBK$$dEBLCP$$dGW5XE$$dN$T$$dYDX$$dOCLCF$$dAZU$$dUAB$$dCOO$$dUPM$$dIOG$$dVT2
000777914 049__ $$aISEA
000777914 050_4 $$aRC591
000777914 08204 $$a616.2/3806$$223
000777914 1001_ $$aPelaia, Girolamo,$$eauthor.
000777914 24510 $$aAsthma :$$btargeted biological therapies /$$cGirolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
000777914 264_1 $$aCham, Switzerland :$$bSpringer,$$c2017.
000777914 300__ $$a1 online resource
000777914 336__ $$atext$$btxt$$2rdacontent
000777914 337__ $$acomputer$$bc$$2rdamedia
000777914 338__ $$aonline resource$$bcr$$2rdacarrier
000777914 347__ $$atext file$$bPDF$$2rda
000777914 504__ $$aIncludes bibliographical references.
000777914 5050_ $$aIntroduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
000777914 506__ $$aAccess limited to authorized users.
000777914 520__ $$aThis book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
000777914 588__ $$aOnline resource; title from PDF title page (viewed December 15, 2016)
000777914 650_0 $$aAsthma$$xTreatment.
000777914 7001_ $$aVatrella, Alessandro,$$eauthor.
000777914 7001_ $$aMaselli, Rosario,$$eauthor.
000777914 77608 $$iPrint version:$$z3319460056$$z9783319460055$$w(OCoLC)954535651
000777914 852__ $$bebk
000777914 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-46007-9$$zOnline Access$$91397441.1
000777914 909CO $$ooai:library.usi.edu:777914$$pGLOBAL_SET
000777914 980__ $$aEBOOK
000777914 980__ $$aBIB
000777914 982__ $$aEbook
000777914 983__ $$aOnline
000777914 994__ $$a92$$bISE